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Abstract
Background:  TGF-β receptor type I is a mediator of growth inhibitory signals. TGFBR1*6A
(rs11466445) is a common polymorphic variant of the TGF-β receptor I gene and has been
associated with tumour susceptibility. Nevertheless, the role of this polymorphism as a risk factor
for colorectal cancer is controversial. The aim of this study was to assess the association between
TGFBR1*6A  and colorectal cancer, age, sex, tumour location and tumour stage in a Spanish
population.
Methods: The case-control study involved 800 Spanish subjects: 400 sporadic colorectal cancer
patients and 400 age-, sex-, and ethnic-matched controls. The odds ratio (OR) and 95% confidence
interval (95% CI) for the TGFBR1*6A polymorphism were calculated using unconditional logistic
regression adjusted for age and sex. Analysis of somatic mutations at the GCG repeat of TGFBR1
exon 1 and germline allele-specific expression were also conducted to obtain further information
on the contribution of the TGFBR1*6A allele to CRC susceptibility.
Results: There was no statistically significant association between the TGFBR1*6A allele and CRC
(p > 0.05). The OR was 1.147 (95% CI: 0.799–1.647) for carriers of the TGFBR1*6A allele and 0.878
(95% CI: 0.306–2.520) for homozygous TGFBR1*6A individuals compared with the reference. The
frequency of the polymorphism was not affected by age, sex or tumour stage. The TGFBR1*6A allele
was more prevalent among colon tumour patients than among rectal tumour patients. Tumour
somatic mutations were found in only two of 69 cases (2.9%). Both cases involved a GCG deletion
that changed genotype 9A/9A in normal DNA to genotype 9A/8A. Interestingly, these two tumours
were positive for microsatellite instability, suggesting that these mutations originated because of a
deficient DNA mismatch repair system.
Published: 18 June 2009
BMC Cancer 2009, 9:193 doi:10.1186/1471-2407-9-193
Received: 21 January 2009
Accepted: 18 June 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/193
© 2009 Castillejo et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:193 http://www.biomedcentral.com/1471-2407/9/193
Page 2 of 7
(page number not for citation purposes)
Allele-specific expression of the 9A allele was detected in seven of the 14 heterozygous 9A/6A
tumour cases. This could have been caused by linkage disequilibrium of the TGFBR1*6A allele with
mutations that cause allele-specific expression, as was recently suggested.
Conclusion: Our results suggest that the TGFBR1*6A allele does not confer an increased risk of
colorectal cancer in the Spanish population.
Background
Colorectal cancer (CRC) is the main cause of cancer-
related deaths in Spain. Although environmental and
genetic factors associated with cancer have been
described, current knowledge of the genetic basis of color-
ectal cancer is limited. About 5% of colorectal cancer cases
are associated with germline mutations of genes such as
APC, DNA mismatch repair genes, MYH,  SMAD4  and
BMPR1A/ALK3  [1]. The heritability component of the
remaining 95% of cases is unknown.
Low-penetrance cancer susceptibility alleles may increase
the risk of cancer in a manner similar to that of pathogenic
germline mutations in hereditary cancer genes. Trans-
forming growth factor beta (TGF-β) is one of the most
potent inhibitors of cell growth. TGF-β ligands interact
with the type II receptor and then bind to the type I recep-
tor, sending a signal to the nucleus through SMAD pro-
teins [2]. Inhibition of TGF function causes unrestricted
cell growth because of a lack of growth inhibition. Thus,
germline mutations of TGFBR2 and SMAD4 may predis-
pose to the development of hereditary non-polyposis
colorectal cancer and juvenile polyposis, respectively [3].
Recently, it has been suggested that a mouse model carry-
ing a germline Tgfbr1 haploinsufficiency has constitu-
tively reduced TGF-beta signalling that significantly
enhances the development of colorectal cancer [4].
Polymorphisms of various genes associated with the TGF-
β pathway have been described as cancer risk factors.
TGFBR1*6A  (rs11466445) is a common polymorphic
variant of the TGF-β receptor I gene. It has been suggested
that the TGFBR1*6A allele is a low-penetrance susceptibil-
ity factor for colorectal cancer [5-7]. This variant of
TGFBR1 is generated by deletion of three GCG triplets that
code for three alanine molecules within a nine alanine
(*9A) stretch sequence at exon 1. The TGFBR1*6A allele
encodes a type I receptor with reduced growth-inhibitory
signalling activity [5]. Two meta-analyses, which included
12 case-control studies, have shown that TGFBR1*6A is a
candidate tumour-susceptibility allele, is present in 13.7%
of the general population and increases the risk of cancer
by approximately 24% [6,7]. Somatic acquisition of this
trinucleotide variant has also been reported in colon can-
cer, supporting its role as a cancer risk allele [8]. Moreover,
it has been proposed that TGFBR1*6A is responsible for a
proportion of patients with hereditary non-polyposis
colorectal cancer syndrome [9]. In contrast, based on their
case-control study and another meta-analysis [10],
Skoglund et al. [10] suggested that this variant is not asso-
ciated with colorectal cancer. Similarly, others have
reported that there is no association between the
TGFBR1*6A allele and prostate [11], lung [12] or bladder
[13] cancer. On the other hand, Valle et al. [14] recently
suggested that germline allele-specific expression (ASE) of
the TGFBR1 gene is dominantly inherited, segregates in
families and occurs in sporadic CRC cases. This ASE con-
fers a substantially increased risk of CRC (OR: 8.7; 95%
CI: 2.6–29.1). Moreover, the authors claim that the
TGFBR1*6A allele is probably in linkage disequilibrium
with one of the putative mutations that causes ASE, but
TGFBR1*6A per se does not cause ASE. The causative germ-
line changes have not been identified.
Because of this controversy, we conducted a case-control
study of the TGFBR1*9A/6A  polymorphism, including
mutational and ASE analyses, to clarify the effect of the
TGFBR1*6A polymorphism on the risk of colorectal can-
cer in our population.
Methods
Subjects
A total of 400 sporadic CRC cases and 400 controls from
the Elche University Hospital and Castellon Provincial
Hospital tissue banks were analysed. Written consent to
be included in the tissue banks was obtained from each
patient. Patients diagnosed with a familial cancer syn-
drome were excluded.
This was a hospital-based case-control study. Controls
with no personal history of cancer, selected with diag-
noses considered unrelated to the exposures of interest,
were selected from the same hospitals and matched with
cases for age, sex and race/ethnicity. The study was
approved by the ethical committees of the Elche Univer-
sity Hospital and the Castellon Provincial Hospital.
The median age at diagnosis of CRC was 70 years (range
22–93 years) and that of the controls was 72 years (range
23–98 years). The sex distribution was 41.8% female (n =
167) and 58.2% male (n = 233) for colorectal cancer
patients and 53.2% female (n = 213) and 46.8% male (n
= 187) for the controls.BMC Cancer 2009, 9:193 http://www.biomedcentral.com/1471-2407/9/193
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Of the CRC cases, 24% had proximal colon tumours,
33.75% had distal colon tumours, 9.25% had sigma-rec-
tum tumours and 25% had rectal tumours. In 8% of cases,
the location of the tumour was unknown. Cases were clas-
sified according to tumour stage as low stage (stages I and
II: 78.5% of cases) or high stage (stages III and IV: 21.5%
of cases) (Table 1).
DNA and RNA samples
DNA for the case-control study: Control DNA was
obtained from peripheral blood samples (n = 400). DNA
was isolated from the non-tumour colorectal tissue (n =
400) of cases after mechanical homogenization (Tissue-
Lyser, Qiagen, Valencia, CA). DNA isolation was per-
formed using the EZ1 DNA Tissue kit and the EZ1 BioRobot
(Qiagen, Valencia, CA) according to the manufacturers'
instructions.
DNA for the TGFBR1 exon 1 tumour mutation: Tumour
tissue DNA was isolated after mechanical homogeniza-
tion of colorectal tumour tissues (n = 69) as described pre-
viously.
RNA extraction: RNA was isolated from normal colorectal
tissue samples from 14 heterozygous 9A/6A CRC patients
after mechanical homogenization using the EZ1 RNA Tis-
sue kit and the EZ1 BioRobot (Qiagen, Valencia, CA).
cDNA synthesis: A retrotranscription reaction was per-
formed using Reverse Transcription Reagents, random prim-
ers (Applied Biosystems, Foster City, CA) and 200–1000 ng
of RNA.
Analysis of the TGFBR1 exon 1 polymorphism, 
TGFBR1*9A/6A
Genotyping of the TGFBR1 exon 1 polymorphism was
conducted in the case-control study and used for the
somatic mutation and ASE analyses. Genotype was
assessed using PCR amplification and capillary electro-
phoresis. The PCR primers were CCACAGGCGGTGGCG-
GCGGGACCATG (5'-labelled with 6-FAM) for TGFBR1F
and CGTCGCCCCCGGGAGCAGCGCCGC for TGFBR1R.
PCR amplification was done using the Amplitaq Gold
PCR Master Mix 2× in a total volume of 25 μl containing
1 M betaine (Sigma Aldrich). The PCR was run for 35
cycles at 94°C for 30 s and 72°C for 90 s followed by a 10
min final extension at 72°C. PCR products and size stand-
ards (Genescan 500 ROX size standard; Applied Biosystems,
Foster City, CA) were diluted in HiDi Formamide (Applied
Biosystems, Foster City, CA) and then resolved by capillary
electrophoresis (ABI 3100 Avant, Applied Biosystems, Foster
City, CA) using POP6 as polymer. GeneScan software was
used for analysis of PCR fragments (Applied Biosystems,
Foster City, CA). Representative cases for each genotype
were sequenced directly to confirm allele sizes (data not
shown). A PCR product size of 119 bp corresponded to
the most common allele, *9A, whereas a product size of
110 bp corresponded to the *6A allele.
Microsatellite instability (MSI) status
A subset of colorectal tumour DNAs from 120 patients
was screened for MSI status using five mononucleotide
markers (BAT26, BAT25, NR21, NR24 and NR27) and
multiplex PCR as previously described by Buhard et al.
[15].
Allele-specific expression of heterozygous *6A/*9A 
individuals
Fourteen heterozygous 9A/6A CRC cases were included in
the ASE analysis. TGFBR1 exon 1 amplicons generated
from normal genomic DNA and corresponding normal
cDNA were run in parallel. The ASE ratio was calculated
by normalizing the ratio between the peak areas of the
two alleles in cDNA with the same parameters in genomic
DNA. A threshold ratio of a 33% difference was used to
define ASE-positive cases [14].
Statistical analysis
The Hardy-Weinberg equilibrium was checked among the
control and case populations. In the case-control study,
we estimated the odds ratio (OR) and 95% confidence
interval (95% CI) for the TGFBR1*6A  polymorphism
using unconditional logistic regression adjusted for age
and sex. We analysed for potential effect modification by
age using an analysis stratified according to median age at
diagnosis (≤ 70 years or >70 years). A χ2 test was used to
evaluate differences in TGFBR1*6A  carrier frequencies
between the tumour and control groups and to analyse
the association between the polymorphism and the clini-
cal and pathological factors. A probability level of < 0.05
was considered significant.
Results
Case-control study
The genotype distribution in the case and control popula-
tions did not deviate significantly from that expected for a
Table 1: TGFBR1 rs11466445 genotype frequency according to 
tumour location and stage (UK: unknown)
Specimens n 9/9 6/9 6/6 p
Tumour location
Proximal colon 93 77 15 1
Distal colon 135 99 34 2 p = 0.109
Rectum 100 88 10 2 p = 0.024
Rectum sigma 37 32 4 1
UK 35
Stage
I-II (low) 139 108 28 3
III-IV (high) 38 31 7 0 p = 0.66
UK 223BMC Cancer 2009, 9:193 http://www.biomedcentral.com/1471-2407/9/193
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population in Hardy-Weinberg equilibrium (p = 0.295 for
cases and p = 0.033 for controls). The allele frequencies
for the TGFBR1*6A allele were 0.101 and 0.092 for cases
and controls, respectively. Genotype distributions for
cases and controls are presented in Table 2. No significant
association was observed between the TGFBR1*6A allele
and colorectal cancer incidence in our population (p =
0.517). The crude ORs were 1.147 (95% CI: 0.799–1.647)
for carriers of the TGFBR1*6A allele and 0.878 (95% CI:
0.306–2.520) for TGFBR1*6A  homozygous individuals
compared with the reference (homozygous TGFBR1*9A).
There was no statistically significant association when the
OR was adjusted for age and sex. When we analysed the
cases according to clinical stage, we detected no significant
difference in the TGFBR1*6A allele distribution between
low and high stages (p = 0.66) (Table 1). On the other
hand,  TGFBR1*6A  allele carriers were more prevalent
among colon (proximal plus distal) cancer patients than
rectal cancer patients (p = 0.024) (Table 1).
Frameshift somatic mutation at TGFBR1 exon 1
First, we screened colorectal tumour DNA from 120
patients for MSI status. We found evidence of MSI in 14
cases (14/120, 11.67%). Two of 14 MSI tumours
(14.29%) had a deletion of a GCG triplet. All 14 MSI cases
were homozygous for the TGFBR1*9A  allele. Both
mutated cases were genotyped as heterozygous 9A/8A.
These results were confirmed by direct sequencing (Figure
1). To determine whether these somatic mutations are
specific for MSI tumours, we analysed tumour DNA from
55 cases that were homozygous for the TGFBR1*9A allele
and were MSI-negative. None of these 55 cases had a
mutation of this GCG repeat (p = 0.039; two-tailed chi
square test).
Allele-specific expression in heterozygous *6A/*9A 
individuals
In the genotyping experiments, comparisons between
peak areas generated from heterozygous individuals from
gDNA and cDNA enabled us to obtain information about
the principally expressed allele and the relative level of its
expression. Seven of 14 cases had differences greater than
33% and were considered ASE-positive. Interestingly, all
seven cases with ASE over-expressed the TGFBR1*9A allele
(Figure 2).
Discussion
There is evidence that common variants of the TGF-β
pathway alter TGF-β signalling and modify cancer risk.
The TGFBR1*6A variant has been associated with breast,
ovarian and haematological malignancies [6,9]. Recent
studies suggest that the association of the TGFBR1*6A
allele with colon cancer is either weak (OR: 1.2; 95% CI:
1.01–1.43) [7] or of borderline significance (OR: 1.13;
95% CI: 0.98–1.30) [10].
In association studies, contradictory conclusions may
arise from population stratification or inappropriate sam-
ple size. We determined a priori that our study with 400
sporadic CRC cases and 400 matched controls would ena-
ble us to detect an OR of 2.0 for 9A/6A heterozygous indi-
viduals (assuming a frequency of 0.15 in controls) and an
OR of 3.0 for 6A/6A homozygous individuals (assuming a
frequency of 0.0175 in controls) with 80% power (two-
sided test, alpha level = 5%).
Our results did not show a statistically significant associa-
tion (p = 0.517; OR: 1.147; 95% CI: 0.799–1.647), which
is in agreement with Skoglund et al. [10]. To our knowl-
edge, the only previous study of this polymorphism in a
Spanish population is one that was included in the meta-
analysis of Pasche et al. [7]. That case-control study was
performed with 298 controls, 237 sporadic CRC cases and
275 sporadic breast cancers. When data for both types of
tumour were pooled, a significant increase in cancer risk
was associated with TGFBR1*6A carriers (OR: 1.60; 95%
CI: 1.10–2.31). The study did not provide information
specifically about CRC or about sex matching between the
groups. Zhang et al. (2005) suggested that the 12 case-
control studies of Pasche [7] had marginally significant
heterogeneity when pooled and questioned the associa-
tion between TGFBR1*6A  and increased risk of cancer
[16]. Similar doubts have been raised in various studies
involving different types of tumours [11-13] and in a
meta-analysis that included eight case-control studies
[10].
Table 2: TGFBR1 rs11466445 genotype frequency in cases and controls in Spain
TGFBR1 exon 1 genotype Cases
(n = 400)
number (%)
Controls
(n = 400)
number (%)
OR (95%CI) p
9A/9A, 325 (81.25) 333 (83.25) 1 (ref.)
6A/9A, 69 (17.25) 60 (15) 1.178 (0.808–1.718) 0.441
6A/6A, 6 (1.5) 7 (1.75) 0.878 (0.306–2.520) 1
6A/* 75 (18.75) 67 (16.75) 1.147 (0.799–1.647) 0.517BMC Cancer 2009, 9:193 http://www.biomedcentral.com/1471-2407/9/193
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Somatic mutation at exon 1 of the TGFBR1 gene in MSI tumours Figure 1
Somatic mutation at exon 1 of the TGFBR1 gene in MSI tumours. A GCG deletion of the triplet repeat was found in 
two independent cases: a) a PCR fragment resolved by capillary electrophoresis, b) DNA sequence from a wild-type case (*9A/
*9A) and a mutated case (*8A/*9A).
*9A/*9A *9A/*9A
*8A/*9A *8A/*9A
b)
*9A/*9A *9A/*9A
*8A/*9A *8A/*9A Mut Mut
a)
delGCG
wt wtBMC Cancer 2009, 9:193 http://www.biomedcentral.com/1471-2407/9/193
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There was little information on which to base the sample size
for our study because information about this polymorphism
in our population is limited and contradictory results were
reported for another population. The results show that our
study was under-powered for detecting weak associations
between the TGFBR1*6A allele and CRC. The data indicate
that a sample size of 10,000 cases and 10,000 controls is nec-
essary to detect an OR of 1.15 with 80% power using a two-
sided test with an alpha level of 5%.
In the present work, age and sex adjustment did have any
effect on the risk conferred by the TGFBR1*6A allele. Pre-
vious case-control studies provide little information in
this regard.
Interestingly, there was a significant difference in the fre-
quency of the TGFBR1*6A allele between colon and rectal
cancer cases. Moreover, when only colon cancer cases
where considered, there was a difference of borderline sig-
nificance for TGFBR1*6A carriers (p = 0.071) with an OR
= 1.47 (95% CI: 0.979–2.203). No data are available
regarding the risk of colon versus rectal cancer for the
TGFBR1*6A allele because data from colorectal and colon
cancer studies were pooled in the meta-analyses. Further
studies with larger samples are needed to determine if the
variant allele is associated specifically with colon cancer
but not with rectal cancer. If confirmed, this may help
explain the contradictory results in the literature.
Because of the limitation that sample size exerts on asso-
ciation studies, we attempted to extract extra information
from our data to elucidate the susceptibility effect of the
minor allele of this polymorphism. First, we wanted to
know if the GCG repeat is a specific target for frameshift
mutations in MSI colorectal tumours, and in the event, if
somatic acquisition of TGFBR1*6A allele occurs in these
MSI tumours, similar to metastatic CRC [8]. The underly-
ing hypothesis was that if the minor allele in the germline
predisposes to CRC, it might be prevalent in the tumours
themselves through somatic acquisition. Our results show
that the GCG repeat at exon 1 of the TGFBR1 gene is a spe-
cific target for MSI tumours (p = 0.039), but the frequency
of mutations is low (2/14, 14.29%) [17]. Nevertheless,
there was no somatic acquisition of the TGFBR1*6A
allele. Both mutated cases underwent the deletion of just
one GCG triplet. No previous studies have documented
the association between this polymorphism and MSI sta-
tus. Unfortunately, our results did not enable us to clarify
the role of the TGFBR1*6A allele in CRC risk.
An additional strategy was used to address the role of the
minor allele for this polymorphism in CRC. We tested
whether gene expression level differed between the alleles
of the polymorphism because previously reported data
from in vitro models shows that growth inhibitory signal-
ling activity is low for the type I receptor coded by the
TGFBR1*6A allele [5]. We hypothesized that if predomi-
nant expression of the TGFBR1*6A allele exists in the 6A/
9A heterozygous individual, global functional reduction
of the pathway would be evident and would increase the
risk for CRC. Surprisingly, the results of the ASE study
were opposite to what we had expected. The proportion of
ASE positive cases was high (7/14), and there was pre-
dominant expression of the TGFBR1*9A allele in all seven
ASE positive cases. The correct interpretation of our results
became evident after the recent publication of the study of
Valle  et al. [14]. The authors concluded that ASE of
TGFBR1 is a major contributor to genetic predisposition
for CRC (OR: 8.7; 95% CI: 2.6–29.1). They were unable to
determine the causative mechanism of the ASE but the
haplotype data suggested that ancestral mutations were
implicated. One of the putative mutations that causes ASE
is probably in linkage disequilibrium with the
TGFBR1*6A allele but is not itself causative of ASE. Our
results are in agreement with those of Valle et al. in that
about 50% of 6A/9A heterozygous individuals have ASE
and the 6A allele is expressed at a low level in all cases. The
linkage disequilibrium between ASE and the TGFBR1*6A
allele could explain the contradictory results in the litera-
ture on the association between this polymorphism and
CRC.
Conclusion
The case-control study did not show a statistical associa-
tion between the TGFBR1*6A allele and CRC, age, sex or
tumour stage. The differences in haplotype frequencies
between colon and rectal tumour patients should be con-
Allele-specific expression of heterozygous *6A/*9A individu- als Figure 2
Allele-specific expression of heterozygous *6A/*9A 
individuals. The over-expressed allele and the ratio of over-
expression are presented. The ASE threshold was defined as 
33%.
25
50
75
100
*6A allele
*9A alleleBMC Cancer 2009, 9:193 http://www.biomedcentral.com/1471-2407/9/193
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firmed by larger series. The somatic mutations that
affected the GCG repeat in this study are a consequence of
deficient MMR function. The ASE results suggest that there
is linkage disequilibrium between the TGFBR1*6A allele
and the mutations that cause ASE. Taken together, our
results strongly suggest that the TGFBR1*6A allele does
not confer an increased risk of colorectal cancer in the
Spanish population.
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